SOUTHLAKE, TX, Sept. 20, 2022 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences HSCS HSCSW))) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to an EKG (also known as an EKG) to maximize the clinical usefulness of an EKG by detecting cardiac dysfunction , announced today that it has been granted a patent by the United States Patent and Trademark Office (USPTO) for ECG quantification of echocardiographic measurements of diastolic heart function using AI methods.

Diastolic dysfunction (impaired heart relaxation) is an important predictor of overall heart health because it is affected by all the usual pathologic processes of heart disease and is a sensitive predictor of cardiovascular dysfunction. Diastolic dysfunction is considered one of the earliest signs of heart disease and typically occurs when a patient is still asymptomatic.

Today, the heart’s diastolic function must be assessed in a specialized cardiac setting, typically using echocardiography-based imaging. Historically, ECGs played only a limited, if any, role in the assessment of cardiac dysfunction and therefore the ability to assess diastolic heart function using an ECG would make it a far more valuable cardiac screening tool, particularly in the frontline or at the point-of-care clinical settings.

HeartSciences’ first device, the MyoVista® wavelet ECG (wavECG™) ??uses AI machine learning to detect cardiac dysfunctions that cannot be diagnosed with current conventional ECGs. His first algorithm was designed to provide diagnostic information related to impaired cardiac relaxation associated with diastolic dysfunction and all traditional ECG information in a single test.

Andrew Simpson, Chief Executive Officer of HeartSciences, stated, “The ECG is a ubiquitous, relatively inexpensive, simple and rapid test used in a variety of clinical settings by a…